Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
Crit Care
.
2020 Jul 9;24(1):407.
doi: 10.1186/s13054-020-03144-6.
Author
Karim Bendjelid
1
2
3
Affiliations
1
Cardiovascular Unit, Intensive Care Division, University Hospitals, Geneva, Switzerland. karim.bendjelid@hcuge.ch.
2
Geneva Hemodynamic Research Group, Geneva, Switzerland. karim.bendjelid@hcuge.ch.
3
Faculty of Medicine, Geneva, Switzerland. karim.bendjelid@hcuge.ch.
PMID:
32646518
PMCID:
PMC7347253
DOI:
10.1186/s13054-020-03144-6
No abstract available
Keywords:
ACE2; Angiotensin; SARS-CoV-2-ACE2.
Publication types
Letter
Comment
MeSH terms
Angiotensin II
Betacoronavirus*
COVID-19
Coronavirus Infections*
Humans
Pandemics*
Pneumonia, Viral*
SARS-CoV-2
Substances
Angiotensin II